Focal Targeted Therapy Will Be a Future Treatment Modality for Early Stage Prostate Cancer

European Urology, Supplements

Volumn 8, Issue 5, 2009, Pages 424-432

  de la Rosette, Jean J M C H ^a   Mouraviev, Vladimir ^a   Polascik, Thomas J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Focal ablation; Focal therapy; Prostate cancer

Indexed keywords

BIOPSY TECHNIQUE; BLADDER FUNCTION; CANCER CONTROL; CANCER EPIDEMIOLOGY; CANCER LOCALIZATION; CANCER SCREENING; CANCER SURGERY; CRYOSURGERY; EARLY CANCER; ELECTROPORATION; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; INTESTINE FUNCTION; MOLECULAR IMAGING; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN PRESERVATION; OUTCOME ASSESSMENT; PARTIAL MASTECTOMY; PATIENT SELECTION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE SURGERY; QUALITY OF LIFE; REVIEW; SEXUAL FUNCTION; SUBTOTAL GLANDULAR ABLATION; SURGICAL RISK; SURGICAL TECHNIQUE; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT INDICATION; TREATMENT PLANNING; TUMOR BIOPSY; URINE INCONTINENCE;

EID: 60049100243     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2009.01.005     Document Type: Review

References (55)

1. Walsh P.C., Partin A.W., and Epstein J.I. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 152 (1994) 1831-1836
2. Stamey T.A., Donaldson A.N., Yemoto C.E., McNeal J.E., Sozen S., and Gill H. Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: epidemiologic significance of annual changes. J Urol 160 (1998) 2412-2417
3. Cooperberg M.R., Broering J.M., Kantoff P.W., and Carroll P.R. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 178 (2007) S14-S19
4. Polascik T.J., Mayes J.M., Sun L., Madden J.F., Moul J.W., and Mouraviev V. Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. Prostate 68 (2008) 1380-1386
5. Eichelberger L.E., Koch M.O., Eble J.N., Ulbright T.M., Juliar B.E., and Cheng L. Maximum tumor diameter is an independent predictor of prostate-specific antigen recurrence in prostate cancer. Mod Pathol 18 (2005) 886-890
6. Yoon G.S., Wang W., Osunkoya A.O., Lane Z., Partin A.W., and Epstein J.I. Residual tumor potentially left behind after local ablation therapy in prostate adenocarcinoma. J Urol 179 (2008) 2203-2206 discussion 2206
7. Meiers I., Waters D.J., and Bostwick D.G. Preoperative prediction of multifocal prostate cancer and application of focal therapy: review 2007. Urology 70 (2007) 3-8
8. Cheng L., Jones T.D., Pan C.X., Barbarin A., Eble J.N., and Koch M.O. Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens. Mod Pathol 18 (2005) 1022-1026
9. Djavan B., Susani M., Bursa B., Basharkhah A., Simak R., and Marberger M. Predictability and significance of multifocal prostate cancer in the radical prostatectomy specimen. Tech Urol 5 (1999) 139-142
10. Stanford J.L., Feng Z., Hamilton A.S., et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 283 (2000) 354-360
11. Onik G., Narayan P., Vaughan D., Dineen M., and Brunelle R. Focal "nerve-sparing" cryosurgery for treatment of primary prostate cancer: a new approach to preserving potency. Urology 60 (2002) 109-114
12. Onik G., Vaughan D., Lotenfoe R., Dineen M., and Brady J. Male lumpectomy": focal therapy for prostate cancer using cryoablation. Urology 70 (2007) 16-21
13. Bahn D.K., Silverman P., Lee Sr. F., Badalament R., Bahn E.D., and Rewcastle J.C. Focal prostate cryoablation: initial results show cancer control and potency preservation. J Endourol 20 (2006) 688-692
14. Lambert E.H., Bolte K., Masson P., and Katz A.E. Focal cryosurgery: encouraging health outcomes for unifocal prostate cancer. Urology 69 (2007) 1117-1120
15. Ellis D.S., Manny Jr. T.B., and Rewcastle J.C. Focal cryosurgery followed by penile rehabilitation as primary treatment for localized prostate cancer: initial results. Urology 70 (2007) 9-15
16. Muto S., Yoshii T., Saito K., Kamiyama Y., Ide H., and Horie S. Focal therapy with high-intensity focused ultrasound in the treatment of localized prostate cancer. Jpn J Clin Oncol 38 (2008) 192-199
17. Jones J.S. Prostate cancer: are we over-diagnosing-or under-thinking?. Eur Urol 53 (2008) 10-12
18. Bangma C.H., Roemeling S., and Schroder F.H. Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol 25 (2007) 3-9
19. Ahmed H.U., Pendse D., Illing R., Allen C., van der Meulen J.H., and Emberton M. Will focal therapy become a standard of care for men with localized prostate cancer?. Nat Clin Pract Oncol 4 (2007) 632-642
20. Polascik T.J., and Mouraviev V. Focal therapy for prostate cancer. Curr Opin Urol 18 (2008) 269-274
21. Jones J.S. Focal or subtotal therapy for early stage prostate cancer. Curr Treat Options Oncol 8 (2007) 165-172
22. Cooperberg M.R., Lubeck D.P., Meng M.V., Mehta S.S., and Carroll P.R. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 22 (2004) 2141-2149
23. Klotz L. Active surveillance for prostate cancer: trials and tribulations. World J Urol 26 (2008) 437-442
24. Klotz L. Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol 24 (2006) 46-50
25. Mouraviev V., and Polascik T.J. Avoiding surgery in prostate cancer patients with low-risk disease. Future Medicine Therapy 5 (2008) 25-36
26. Eggener S.E., Scardino P.T., Carroll P.R., et al. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol 178 (2007) 2260-2267
27. Ahmed H.U., and Emberton M. Active surveillance and radical therapy in prostate cancer: can focal therapy offer the middle way?. World J Urol 26 (2008) 457-467
28. Trachtenberg J., Bogaards A., Weersink R.A., et al. Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response. J Urol 178 (2007) 1974-1979 discussion 1979
29. Trachtenberg J, Haider M, Weersink R, Davidson S, Wilson B, Gertner M. Image guided laser thermotherapy for focal ablation of prostate cancer. In: Abstracts of the Eighth Annual Meeting of the Society of Urologic Oncology: Extraordinary Opportunities for Discovery; 2007. p. 96-7.
30. Rukstalis D.B., Goldknopf J.L., Crowley E.M., and Garcia F.U. Prostate cryoablation: a scientific rationale for future modifications. Urology 60 (2002) 19-25
31. Polascik T.J., Mayes J.M., and Mouraviev V. From whole-gland to targeted cryoablation for the treatment of unilateral or focal prostate cancer. Oncology (Williston Park) 22 (2008) 900-906 discussion 906-7, 914
32. Uchida T., Sanghvi N.T., Gardner T.A., et al. Transrectal high-intensity focused ultrasound for treatment of patients with stage T1b-2N0M0 localized prostate cancer: a preliminary report. Urology 59 (2002) 394-398 discussion 398-9
33. Moore C.M., Nathan T.R., Lees W.R., et al. Photodynamic therapy using meso tetra hydroxy phenyl chlorin (mthpc) in early prostate cancer. Lasers Surg Med 38 (2006) 356-363
34. Lips IM, van Gils CH, van der Heide UA, Kruger AE, van Vulpen M. Health-related quality of life 3 years after high-dose intensity-modulated radiotherapy with gold fiducial marker-based position verification. BJU Int. In press.
35. Nguyen P.L., Trofimov A., and Zietman A.L. Proton-beam vs intensity-modulated radiation therapy. Which is best for treating prostate cancer?. Oncology (Williston Park) 22 (2008) 748-754 discussion 754, 757
36. Vogl T.J., Mayer H.P., Zangos S., Selby Jr. J.B., Ackermann H., and Mayer F.B. Prostate cancer: MR imaging-guided galvanotherapy-technical development and first clinical results. Radiology 245 (2007) 895-902
37. Onik G., Mikus P., and Rubinsky B. Irreversible electroporation: implications for prostate ablation. Technol Cancer Res Treat 6 (2007) 295-300
38. Wink M., Frauscher F., Cosgrove D., et al. Contrast-enhanced ultrasound and prostate cancer; a multicentre European research coordination project. Eur Urol 54 (2008) 982-993
39. Zhai L, Dahl J, Madden J, et al. Three-dimensional acoustic radiation force impulse (ARFI) imaging of human prostate in vivo. Proc 2008 IEEE International Ultrasonics Symposium. In press. doi:10.1109/ULTSYM.2008.0131.
40. Braeckman J., Autier P., Garbar C., et al. Computer-aided ultrasonography (histoscanning): a novel technology for locating and characterizing prostate cancer. BJU Int 101 (2008) 293-298
41. Haider MA. Magnetic resonance imaging in localization of prostate cancer. Abstracts from the First International Workshop on Focal Therapy and Imaging of Prostate Cancer February 21-22, 2008 (#13). The Duke Comprehensive Cancer Center and the Duke Prostate Center, Durham, North Carolina. J Endourol 2008; 22:1098.
42. Puech P, Potiron E, Lemaitre L, Leroy X, Biserte L, Villers A. Diagnostic accuracy of dynamic contrast-enhanced pelvic-phased array MRI for detection of localized prostate cancer: correlation with radical prostatectomy findings. Abstracts from the First International Workshop on Focal Therapy and Imaging of Prostate Cancer February 21-22, 2008 (#14). The Duke Comprehensive Cancer Center and the Duke Prostate Center, Durham, North Carolina. J Endourol 2008; 22:1098.
43. Kurhanewicz J., Bok R., Nelson S.J., and Vigneron D.B. Current and potential applications of clinical 13c MR spectroscopy. J Nucl Med 49 (2008) 341-344
44. Nelson P, Coleman I, Wu M, et al. A molecular correlate to the Gleason grading system for prostate cancer. Abstracts from the First International Workshop on Focal Therapy and Imaging of Prostate Cancer February 21-22, 2008 (#4). The Duke Comprehensive Cancer Center and the Duke Prostate Center, Durham, North Carolina. J Endourol 2008; 22:1094-5.
45. Barzell W.E., and Melamed M.R. Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate--a 4-year experience. Urology 70 (2007) 27-35
46. Onik G., and Barzell W. Transperineal 3D mapping biopsy of the prostate: an essential tool in selecting patients for focal prostate cancer therapy. Urol Oncol 26 (2008) 506-510
47. Narayanan R., Werahera P.N., Barqawi A., et al. Adaptation of a 3D prostate cancer atlas for transrectal ultrasound guided target-specific biopsy. Phys Med Biol 53 (2008) N397-N406
48. Partin A.W., Mangold L.A., Lamm D.M., Walsh P.C., Epstein J.I., and Pearson J.D. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 58 (2001) 843-848
49. Kattan M.W., Eastham J.A., Stapleton A.M., Wheeler T.M., and Scardino P.T. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90 (1998) 766-771
50. D'Amico A.V., Moul J., Carroll P.R., Sun L., Lubeck D., and Chen M.H. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 21 (2003) 2163-2172
51. Polascik T, Mayes J, Schroeck F, et al. Patient selection for hemi-ablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy. Cancer. In press.
52. Iczkowski K.A., Hossain D., Torkko K.C., et al. Preoperative prediction of unifocal, unilateral, margin-negative, and small volume prostate cancer. Urology 71 (2008) 1166-1171
53. Polascik T.J., Mayes J.M., and Mouraviev V. Nerve-sparing focal cryoablation of prostate cancer. Curr Opin Urol. 19 (2009) 182-187
54. Mouraviev V., Mayes J.M., Sun L., Madden J.F., Moul J.W., and Polascik T.J. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer 110 (2007) 906-910
55. Moul J.W., Mouraviev V., Sun L., Schroeck F.R., and Polascik T.J. Prostate cancer: the new landscape. Curr Opin Urol. 19 (2009) 154-161